Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APTONASDAQ:ATRANASDAQ:AVRONASDAQ:GNFTNASDAQ:MGTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$1.22-0.8%$1.59$1.20▼$8.70$19.18M1.2987,669 shs56,221 shsATRAAtara Biotherapeutics$0.71$0.72$0.20▼$3.02$85.31M0.692.70 million shs697,941 shsAVROAVROBIO$1.19-1.7%$1.28$0.57▼$1.70$53.38M1.22272,822 shs348,448 shsGNFTGenfit$3.45$3.60$2.89▼$4.75$171.66M1.0814,909 shs3,539 shsMGTXMeiraGTx$4.86-1.4%$5.88$3.49▼$8.35$312.11M1.29154,670 shs109,845 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences0.00%-3.15%-20.65%-41.15%-82.98%ATRAAtara Biotherapeutics+3.04%+5.43%+3.04%+23.81%-75.56%AVROAVROBIO+0.83%-3.97%-5.47%-9.02%+34.43%GNFTGenfit0.00%-5.51%-6.79%-13.38%-8.04%MGTXMeiraGTx-1.79%-8.87%-22.48%-24.85%-8.70%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTOAptose Biosciences1.1555 of 5 stars3.53.00.00.00.60.00.6ATRAAtara Biotherapeutics3.9919 of 5 stars3.02.00.04.73.12.50.6AVROAVROBIO1.2043 of 5 stars3.03.00.00.00.61.70.6GNFTGenfit0.8154 of 5 stars3.53.00.00.00.60.00.0MGTXMeiraGTx3.9297 of 5 stars3.54.00.04.80.01.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTOAptose Biosciences3.00Buy$19.801,522.95% UpsideATRAAtara Biotherapeutics2.00Hold$28.003,817.73% UpsideAVROAVROBIO2.00Hold$2.0068.07% UpsideGNFTGenfit3.00Buy$11.00219.30% UpsideMGTXMeiraGTx3.00Buy$25.67428.12% UpsideCurrent Analyst RatingsLatest MGTX, GNFT, APTO, AVRO, and ATRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/5/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.004/3/2024APTOAptose BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$5.003/27/2024APTOAptose BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.003/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.002/1/2024APTOAptose BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.00 ➝ $5.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/AATRAAtara Biotherapeutics$8.57M9.95N/AN/A($0.97) per share-0.74AVROAVROBION/AN/A$0.28 per share4.19$2.13 per shareN/AGNFTGenfit$41.31M4.16N/AN/A$1.48 per share2.33MGTXMeiraGTx$14.02M22.26N/AN/A$2.17 per share2.24Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTOAptose Biosciences-$51.21M-$7.72N/AN/AN/AN/A-458.70%-205.30%5/13/2024 (Estimated)ATRAAtara Biotherapeutics-$276.13M-$2.62N/AN/AN/A-3,220.88%-783.31%-122.34%5/13/2024 (Estimated)AVROAVROBIO$12.16M-$0.10N/AN/AN/AN/A-74.86%-65.11%5/9/2024 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)MGTXMeiraGTx-$84.03M-$1.47N/A5.40N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)Latest MGTX, GNFT, APTO, AVRO, and ATRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ATRAAtara Biotherapeutics-$0.61-$0.56+$0.05-$0.56$2.45 million$4.25 million3/26/2024Q4 2023APTOAptose Biosciences-$1.48-$1.44+$0.04-$1.44N/AN/A3/14/2024Q4 2023MGTXMeiraGTx-$0.46-$0.47-$0.01-$1.36$10.13 million$2.04 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTOAptose BiosciencesN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AAVROAVROBION/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTOAptose BiosciencesN/A0.780.78ATRAAtara BiotherapeuticsN/A0.720.65AVROAVROBION/A15.7815.78GNFTGenfit0.922.942.94MGTXMeiraGTx0.622.382.38OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTOAptose Biosciences26.62%ATRAAtara Biotherapeutics70.90%AVROAVROBIO62.63%GNFTGenfit2.24%MGTXMeiraGTx67.48%Insider OwnershipCompanyInsider OwnershipAPTOAptose Biosciences9.53%ATRAAtara Biotherapeutics4.50%AVROAVROBIO9.20%GNFTGenfit4.20%MGTXMeiraGTx9.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPTOAptose Biosciences3115.72 million14.22 millionNo DataATRAAtara Biotherapeutics334119.36 million113.99 millionOptionableAVROAVROBIO1344.86 million40.73 millionOptionableGNFTGenfit15949.83 million47.74 millionNot OptionableMGTXMeiraGTx41964.22 million57.99 millionOptionableMGTX, GNFT, APTO, AVRO, and ATRA HeadlinesSourceHeadlineMeiraGTx to Participate in Upcoming Investor Conferencesglobenewswire.com - April 24 at 4:30 PMMeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conferenceglobenewswire.com - April 18 at 4:30 PMMGTX Apr 2024 12.500 callfinance.yahoo.com - March 17 at 2:29 AMBuy Rating Affirmed: Meiragtx Holdings’ Promising Pipeline and Strategic Partnerships Set Stage for Growthmarkets.businessinsider.com - March 15 at 11:23 PMMGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q4 2023investorplace.com - March 14 at 10:03 PMRecap: MeiraGTx Hldgs Q4 Earningsbenzinga.com - March 14 at 8:49 PMMeiraGTx Holdings PLC Reports Notable Clinical Progress Amidst Financial Challenges in 2023hk.finance.yahoo.com - March 14 at 3:48 PMMeira Retreats on Financial Figuresbaystreet.ca - March 14 at 10:48 AMMeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimateszacks.com - March 14 at 10:46 AMMeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updatesglobenewswire.com - March 14 at 8:30 AMMeiraGTx Holdings plc (NASDAQ:MGTX) stock most popular amongst private equity firms who own 28%, while individual investors hold 26%finance.yahoo.com - February 26 at 1:35 PMMGTX Mar 2024 12.500 callfinance.yahoo.com - February 17 at 10:20 AMMeiraGTx: Bota-Vec Program Advancing With Milestones Being Metseekingalpha.com - February 16 at 6:38 PMMeiraGTx Holdings PLC MGTXmorningstar.com - February 15 at 8:13 PMMeiraGTx Holdings: Other Events, Financial Statements And Exhibitscbonds.com - February 15 at 10:12 AMMeiraGTx receives $50 million milestone payment from Janssenthepharmaletter.com - February 14 at 7:52 AMMeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticalsfinance.yahoo.com - February 13 at 10:56 AMWall Street Analysts Think MeiraGTx Holdings PLC (MGTX) Could Surge 217.92%: Read This Before Placing a Betfinance.yahoo.com - January 10 at 4:20 PMMeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisionsfinance.yahoo.com - January 10 at 11:20 AMWall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to Tradefinance.yahoo.com - December 25 at 1:49 PMMeiraGTx Hldgs Stock (NASDAQ:MGTX), Short Interest Reportbenzinga.com - December 24 at 8:21 AMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: NeuroPace (NPCE), Meiragtx Holdings (MGTX) and Jazz Pharmaceuticals (JAZZ)markets.businessinsider.com - December 23 at 12:00 AMMeiraGTx Hldgs Stock (NASDAQ:MGTX) Dividends: History, Yield and Datesbenzinga.com - December 22 at 7:00 PMJ&J bets bigger on MeiraGTx’s eye gene therapybiopharmadive.com - December 22 at 12:06 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAptose BiosciencesNASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Atara BiotherapeuticsNASDAQ:ATRAAtara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.AVROBIONASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.GenfitNASDAQ:GNFTGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.